tiprankstipranks
Legend’s CARVYKTI approved by FDA for second-line treatment of multiple myeloma
PremiumThe FlyLegend’s CARVYKTI approved by FDA for second-line treatment of multiple myeloma
13d ago
Cantor starts Legend Biotech at Overweight on Carvykti expansion
PremiumThe Fly
Cantor starts Legend Biotech at Overweight on Carvykti expansion
17d ago
Legend Biotech initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Legend Biotech initiated with an Overweight at Cantor Fitzgerald
17d ago
Legend Biotech initiated with an Outperform at Raymond James
PremiumThe FlyLegend Biotech initiated with an Outperform at Raymond James
1M ago
Legend Biotech initiated with an Outperform at Raymond James
PremiumThe Fly
Legend Biotech initiated with an Outperform at Raymond James
1M ago
Legend Biotech reports Q4 EPS (40c), consensus (83c)
PremiumThe Fly
Legend Biotech reports Q4 EPS (40c), consensus (83c)
1M ago
Legend Biotech reports outcomes in CARTITUDE-4 study of CARVYKTI
PremiumThe FlyLegend Biotech reports outcomes in CARTITUDE-4 study of CARVYKTI
4M ago
Citi opens ‘positive catalyst watch’ on Legend Biotech
PremiumThe Fly
Citi opens ‘positive catalyst watch’ on Legend Biotech
5M ago
There’s an Opportunity Brewing in These 3 Stocks, Says Goldman Sachs
PremiumStock Analysis & Ideas
There’s an Opportunity Brewing in These 3 Stocks, Says Goldman Sachs
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100